Navigation

Breast cancer - bevacizumab (in combination with a taxane)

Bevacizumab in combination with a taxane for the first-line treatment of HER2 negative metastatic breast cancer (to include a reinitiation of terminated TA147)

Status: History
Expected date of issue: February 2011
Referral date: July 2009
Process: STA
Topic area:
  • Cancer
 

NICE project team

Executive Lead: TBC
Technical Lead: Raisa Sidhu
Communications manager: Laura Gibson
Project manager: Bijal Joshi
Assessment Group / Evidence Review Group: NHS Centre for Reviews & Dissemination and Centre for Health Economics
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 8 March 2010
1st appraisal committee meeting: 17 June 2010
2nd appraisal committee meeting 20 October 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers / Sponsors

  • Roche Products (bevacizumab)

Patient / Carer groups

  • Afiya Trust
  • Age Concern & Help the Aged
  • Black Health Agency
  • Breakthrough Breast Cancer
  • Breast Cancer Campaign
  • Breast Cancer Care
  • Breast Cancer Haven
  • Breast Cancer UK
  • CANCERactive
  • Cancer Black Care
  • Cancer Equality
  • Chinese National Healthy Living Centre
  • Confederation of Indian Organisations
  • Counsel and Care
  • Equalities National Council
  • Helen Rollason Heal Cancer Charity
  • Macmillan Cancer Support
  • Maggie’s Centres
  • Marie Curie Cancer Care
  • Muslim Council of Great Britain
  • Muslim Health Network
  • National Cancer Alliance
  • National Council for Palliative Care
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • Sue Ryder Care
  • Tenovus Cancer Information Centre
  • Women’s Health Concern

Professional groups

  • Association of Cancer Physicians
  • British Association for Services to the Elderly
  • British Geriatrics Society
  • British Institute of Radiology
  • British Oncological Association
  • British Psychosocial Oncology Society
  • Cancer Networks Pharmacists Forum
  • Cancer Research UK
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • Royal College of Radiologists
  • Royal Society of Medicine – Intellectual Disabilities Forum
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • Kensington & Chelsea PCT
  • Milton Keynes PCT
  • Welsh Assembly Government

General

  • Board of Community Health Councils in Wales
  • British National Formulary
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association for Primary Care
  • National Public Health Service for Wales
  • NHS Alliance
  • NHS Confederation
  • NHS Purchasing and Supply Agency
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • Bristol-Myers Squibb Pharmaceuticals (paclitaxel)
  • Eli Lilly & Co (gemcitabine)
  • Hospira (paclitaxel)
  • Sanofi-Aventis (docetaxel)
  • Wockhardt UK (paclitaxel)

Relevant research groups

  • Against Breast Cancer
  • Breast Cancer Hope
  • Breast Cancer Research Trust
  • Cochrane Collaboration – Cochrane Breast Cancer Group
  • Institute of Cancer Research
  • MRC Clinical Trials Unit
  • National Cancer Research Institute
  • National Cancer Research Network
  • National Institute for Health Research
  • Policy Research Institute on Ageing and Ethnicity
  • Pro-Cancer Research Fund
  • Research Institute for the Care of Older People

Evidence review group

  • National Institute for Health Research Health Technology Assessment Programme
  • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • None

Top


 

Project history

Date Update
10 August 2010

In the light of ongoing regulatory reviews, the manufacturer of bevacizumab, Roche, have requested additional time to allow for further clinical evidence to be presented as part of the ACD response. NICE has exceptionally agreed to allow an extension to the timeline to accommodate this.

In accordance with the guide to the single technology appraisal process (section 3.5.34), NICE will have to extend the timelines for this appraisal to allow for a full and comprehensive review of new evidence. The second discussion of this topic will now take place on 20th October 2010.

09 February 2010

Further to our update in December 2009 regarding the non submission from the manufacturer of bevacizumab (in combination with a taxane) for breast cancer, Roche will be submitting evidence in early March 2010.

Consequently, this topic will be discussed at an Appraisal Committee Meeting on 17 June 2010.

11 December 2009 This appraisal is currently suspended because NICE has not received an evidence submission from the manufacturer of bevacizumab.
Top


 

Key documents

This page was last updated: 22 February 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.